Oseroff AR - Search Results

1

Photodynamic therapy for non-melanoma skin cancer.

Fien SM, Oseroff AR. Fien SM, et al. Among authors: oseroff ar. J Natl Compr Canc Netw. 2007 May;5(5):531-40. doi: 10.6004/jnccn.2007.0046. J Natl Compr Canc Netw. 2007. PMID: 17509255 Review.

2

Aminolevulinic acid photodynamic therapy for skin cancers.

Blume JE, Oseroff AR. Blume JE, et al. Among authors: oseroff ar. Dermatol Clin. 2007 Jan;25(1):5-14. doi: 10.1016/j.det.2006.09.005. Dermatol Clin. 2007. PMID: 17126737 Review.

3

Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.

Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Pandey RK, Tsuchida T, Dougherty TJ. Bellnier DA, et al. Among authors: oseroff ar. Cancer Res. 2003 Apr 15;63(8):1806-13. Cancer Res. 2003. PMID: 12702566

4

Photodynamic therapy for nonmelanoma skin cancers. Current review and update.

Zeitouni NC, Oseroff AR, Shieh S. Zeitouni NC, et al. Among authors: oseroff ar. Mol Immunol. 2003 Jul;39(17-18):1133-6. doi: 10.1016/s0161-5890(03)00083-x. Mol Immunol. 2003. PMID: 12835091 Review.

5

Mitochondria-based photodynamic anti-cancer therapy.

Morgan J, Oseroff AR. Morgan J, et al. Among authors: oseroff ar. Adv Drug Deliv Rev. 2001 Jul 2;49(1-2):71-86. doi: 10.1016/s0169-409x(01)00126-0. Adv Drug Deliv Rev. 2001. PMID: 11377804 Review.

6

Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy.

Bellnier DA, Greco WR, Nava H, Loewen GM, Oseroff AR, Dougherty TJ. Bellnier DA, et al. Among authors: oseroff ar. Cancer Chemother Pharmacol. 2006 Jan;57(1):40-5. doi: 10.1007/s00280-005-0015-6. Epub 2005 Nov 5. Cancer Chemother Pharmacol. 2006. PMID: 16001178 Clinical Trial.

7

Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.

Henderson BW, Busch TM, Vaughan LA, Frawley NP, Babich D, Sosa TA, Zollo JD, Dee AS, Cooper MT, Bellnier DA, Greco WR, Oseroff AR. Henderson BW, et al. Among authors: oseroff ar. Cancer Res. 2000 Feb 1;60(3):525-9. Cancer Res. 2000. PMID: 10676629

8

The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.

Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, Morgan J, Pandey RA, Oseroff AR. Liu W, et al. Among authors: oseroff ar. Clin Cancer Res. 2007 Apr 15;13(8):2463-70. doi: 10.1158/1078-0432.CCR-06-1599. Clin Cancer Res. 2007. PMID: 17438106

9

Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy.

Oseroff AR, Shieh S, Frawley NP, Cheney R, Blumenson LE, Pivnick EK, Bellnier DA. Oseroff AR, et al. Arch Dermatol. 2005 Jan;141(1):60-7. doi: 10.1001/archderm.141.1.60. Arch Dermatol. 2005. PMID: 15655143

10

Photodynamic therapy for the treatment of extramammary Paget's disease.

Shieh S, Dee AS, Cheney RT, Frawley NP, Zeitouni NC, Oseroff AR. Shieh S, et al. Among authors: oseroff ar. Br J Dermatol. 2002 Jun;146(6):1000-5. doi: 10.1046/j.1365-2133.2002.04801.x. Br J Dermatol. 2002. PMID: 12072068

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

106 results

Search Page

Filters